4
Changes in Ownership
4D Molecular Therapeutics, Inc. Filed Acc 0000950170-24-083303
Chief Executive Officer sold 12,923 shares at $22.49 ($290,598)
- Chief Executive Officer acquired 12,923 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kirn David Chief Executive Officer | 2024-07-10 | Option exercise 10b5-1 | +11,653 | $14.42 | $168,036 | 1,070,806 | D |
| Kirn David Chief Executive Officer | 2024-07-10 | Option exercise 10b5-1 | +1,270 | $15.78 | $20,041 | 1,072,076 | D |
| Kirn David Chief Executive Officer | 2024-07-10 | Sale 10b5-1 | −12,923 | $22.49 | $290,598 | 1,059,153 | D |
| Derivatives | |||||||
| Kirn David Chief Executive Officer | 2024-07-10 | Option exercise · Stock Option (Right To Buy) 10b5-1 | −11,653 | 565,417 | D | ||
| Kirn David Chief Executive Officer | 2024-07-10 | Option exercise · Stock Option (Right To Buy) 10b5-1 | −1,270 | 148,730 | D | ||
| Open-market sales · 12,923 sh · avg $22.49 · $290,598 | |||||||
Loading xslF345X05/ownership.xml…